













Ris	sk of	Disease Following	g Primary In	ifection	
Age		Disseminated TB/ TB meningitis	Pulmonary TB	No Disease	
< 1 yea	ar	10-20%	30-40%	50%	
1-2 yea	ars	2-5 %	10-20%	75-80%	
2-5 yea	ars	0-5%	5%	95%	
5-10 ye	ears	< 0-5%	2%	98%	
> 10 ye	ears	< 0-5%	10-20%	80-90%	
			Lance	ət Infect Dis 2008; 8: 498	-510



	Total†		US-	US-Born		n-Born
	n	%	n	%	n	%
Major site of disease Pulmonary Pleural Lymphatic Bone or joint Miliary Meningeal Other	11 480 8824 132 1778 156 125 242 217	$ \begin{array}{r} 100.0 \\ 76.9 \\ 1.1 \\ 15.5 \\ 1.4 \\ 1.1 \\ 2.1 \\ 1.9 \\ \end{array} $	8603 6639 92 1313 96 104 204 149	$100.0 \\ 77.2 \\ 1.1 \\ 15.3 \\ 1.1 \\ 1.2 \\ 2.4 \\ 1.7$	2781 2111 36 450 59 21 38 66	$ \begin{array}{r} 100.0 \\ 75.9 \\ 1.3 \\ 16.2 \\ 2.1 \\ 0.8 \\ 1.4 \\ 2.4 \\ \end{array} $

Clinical Syndromes Associated with Pediatric TB		
		Group at Risk
Early disease		
2-6 mo	Uncomplicated lymph node disease	< 10 y
	Progressive Ghon focus	< 1 y or severely compromised
	Miliary TB, TB meningitis or both	< 3 y or severely compromised
4-12 mo	Complicated lymph node disease	> 1 y
	Pleural disease	> 3 y
	Peripheral lymphadenitis	1-10 Y
Late disease		
8-24 mo	Adult-type pulmonary disease	> 10 y
1-3 у	Osteoarticular disease	> 1 y
> 3 y	Urinary tract disease	> 5 y
		N Engl J Med 2012; 367: 34















Diagnostic Tests in TB Lymphadenitis

Location (Year)	Culture (+)	AFB (+)	GI (+)	Culture + GI (+)	NAAT (+)
California (1992) [28]					
Excisional Biopsy	28/30 (93%)	11/30 (37%)	23/30 (77%)	N/A	N/A
FNA	18/29 (62%)	10/29 (35%)	16/29 (55%)	N/A	N/A
France (1999) [9]					
Excisional Biopsy	12/39 (31%)	2/39 (5%)	32/39 (82%)	N/A	N/A
FNA	8/26 (31%)	2/26 (8%)	N/A	N/A	N/A
California (1999) [29]					
FNA	44/238 (18%)	58/238 (24%)	84/238 (35%)	N/A	N/A
India (2000) [30]					
Excisional Biopsy	4/22 (18%)	5/22(23%)	13/22 (59%)	17/22 (77%)	15/22 (68%)
FNA	2/22 (10%)	4/22 (18%)	7/22 (32%)	9/22 (41%)	12/22 (55%)
California (2005) [5]					
Excisional Biopsy	24/34 (71%)	15/39 (38%)	36/31 (88%)	N/A	N/A
FNA	48/77 (62%)	5/19 (26%)	47/76 (62%)	N/A	N/A
UK (2010) [12]					
FNA	65/97 (67%)	22/97 (23%)	77/97 (79%)	88/97 (91%)	N/A
				Clin Infect Dis 2011;	53: 555-564

		11. The second se	
	s versus in Lympna	adenitis	
	ТВ	NTM	
Age range (years)	20-40	1–6	
Sex distribution	F>M	F≥M	
Birth country	TB-endemic	Non-TB-endemic	
HIV infection	Common in HIV-endemic countries Uncommon in developed countries	Rare	
Clinical features	Indolent painless swelling Systemic symptoms: uncommon in HIV-negative, common in HIV-positive	Indolent painless swelling Systemic symptoms: uncommon	
Location	Cervical	Cervicofacial	
Pulmonary disease	Common	Absent	
Tuberculin skin test	Positive	Occasionally positive	
IGRA	Positive	Negative	
Histology	Reactive adenitis	Caseating granuloma	
Treatment	Antibiotics +/- excision	Excision +/- antibiotics	
		A1	

Presenting Symptoms and Signs in > 500 Children with Central Nervous System TB, South Africa, 1985-2005

Symptoms / Signs	Number of patients (%)
Decreased consciousness	356 (70)
Fever	339 (67)
Vomiting	269 (53)
Malaise	263 (52)
Seizures	240 (47)
Weight loss	236 (46)
Cough	164 (32)
Weakness	157 (31)
Headache	128 (25)
Meningeal irritation	445 (98)
Cranial nerve palsies	145 (27)
	Pediatrics 2009; 12

Diagnostic Findings in > 500 Children with Central Nervous System TB, South Africa, 1985-2005

Symptoms / Signs	Number of patients (%)
TST, reactive	304 (61)
Chest radiograph, abnormal	249 (46)
Chest radiograph, miliary	66 (12)
CT, abnormal	165 (70)
CT, basal meningeal enhancement	387 (75)
CT, infarction	164 (32)
CT, tuberculoma	66 (13)
Culture positive, CSF	64 (12)
Culture positive, other specimen	104 (19)
	Pediatrics 2009; 123: e1

Symptoms / Signs	Percent (%) Children
Hepatomegaly	82
Splenomegaly	54
Lymphadenopathy	46
Fever	39
Respiratory distress	34
Meningitis	19
	Ped Infect Dis J 1991; 10:

Primary Reason Evaluated Among Children and Adolescents with TB, United States, 2009-2010

	US-born With Linked TB Case, 188 (100), N (%)	All US-born, 1162 (100), <i>N</i> (%)	Foreign-born With Linked TB Case, 13 (100), <i>N</i> (%)	All Foreign-born, 518 (100), <i>N</i> (%)
Contact investigation	131 (70)	367 (32)	13 (100)	39 (8)
TB symptoms	31 (16)	334 (29)	—	169 (33)
Abnormal radiograph	17 (9)	170 (15)	—	112 (22)
Targeted testing	5 (3)	40 (3)	—	32 (6)
Immigration examination	Not applicable	Not applicable	_	43 (8)
Other	2 (1)	36 (3)		18 (3)
Unknown	2 (1)	215 (19)		105 (20)
UNKNOWN	2 (1)	210 (19)		105 (20)
1				

	All patients (n=113)	Culture-confirmed tuberculosis (n=18)	Highly probable tuberculosis (n=8)	Probable tuberculosis (n=12)	Not tuberculosis (n=63)	Indetermina (n=12)
Age (years)	6-1 (2-1-10-3)	4.6 (1.5-12.7)	8.1 (5.2-11.9)	6 (1-8-10-5)	6-1 (2-0-9-8)	5.4 (2.2-10
Female sex	52 (46%)	8 (44%)	5 (63%)	6 (50%)	27 (43%)	6 (50%)
Symptoms at enrolment						
Cough	108 (96%)	16 (89%)	6 (75%)	12 (100%)	62 (98%)	12 (100%)
Fatigue or lethargy	28 (25%)	8 (44%)	2 (25%)	2 (17%)	16 (25%)	0
Wheezing	16 (14%)	1 (6%)	1 (13%)	3 (25%)	9 (14%)	2 (17%)
Breathing difficulties	47 (42%)	10 (56%)	4 (50%)	8 (67%)	22 (35%)	3 (25%)
Fever	82 (73%)	16 (89%)	6 (75%)	9 (75%)	45 (71%)	6 (50%)
Chest pain	23 (20%)	1 (6%)	0	1(8%)	18 (29%)	3 (25%)
Haemoptysis	4 (4%)	1 (6%)	0	1(8%)	1 (2%)	1 (8%)
Enlarged lymph nodes	12 (11%)	5 (28%)	1 (13%)	1(8%)	5 (8%)	0
Weight loss	55 (49%)	13 (72%)	3 (38%)	5 (42%)	32 (51%)	2 (17%)
Abdominal pains	20 (18%)	5 (28%)	2 (25%)	3 (25%)	9 (14%)	1 (8%)
Malnutrition	60 (53%)	12 (67%)	4 (50%)	5 (42%)	24 (38%)	5 (42%)
HIV infection	33 (29%)	4 (22%)	3 (38%)	7 (58%)*	15 (24%)	4 (33%)
WHO immunological staging						
Not clinically significant	7/33 (21%)	0/4 (0%)	0/3 (0%)	2/7 (29%)	4/15 (27%)	1/4 (25%)
Mild	6/33 (18%)	1/4 (25%)	1/3 (33%)	2/7 (29%)	2/15 (13%)	0/4 (0%)
Advanced	1/33 (3%)	1/4 (25%)	0/3 (0%)	0/7 (0%)	0/15 (0%)	0/4 (0%)
Severe	19/33 (58%)	2/4 (50%)	2/3 (67%)	3/7 (43%)	9/15 (60%)	3/4 (75%)
On antienter visal through at an enlarge	t 12/22 (20%)	2/4 (50%)	1/3 (33%)	2/7 (29%)	7/15 (47%)	1/4(25%)
Positive tuberculin skin test	31/103 (30%)	13/17 (76%)	3/8 (38%)	2/11 (18%)	9/57 (16%)	4/10 (40%)
Positive interferon-y release assay	27/110 (25%)	13/18 (72%)	1/7 (14%)	3/12 (25%)	8/61 (13%)	4/12 (33%)
Positive tuberculin skin test or interferon-γ release assay	47/112 (42%)	17/18 (94%)	3/8 (38%)	4/12 (33%)	15/63 (24%)	4/11 (36%)

